Mangia, Alessandra <br/><br/>
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.  [electronic resource] 

 -  The New England journal of medicine  Jun 2005 
 - 2609-17 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa042608  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Analysis of Variance<br/>Antiviral Agents--administration & dosage<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols<br/>RNA, Viral--blood<br/>Recombinant Proteins<br/>Recurrence<br/>Ribavirin--administration & dosage